Literature DB >> 17119884

[Response prediction--early response evaluation. Consequences for surgical oncology].

J R Siewert1, F Lordick.   

Abstract

Response to perioperative chemotherapy or chemoradiation can hardly be predicted on the basis of molecular marker analyses. In contrast, by means of metabolic and molecular imaging using positron emission tomography, response can be assessed as early as 14 days after the start chemotherapy for many tumors. There is no doubt that the prognosis of patients with surgically resected tumors is much better in the case of a response to chemotherapy or chemoradiation. Important consequences can be deduced from this regarding the indications for perioperative therapies, the radicality of surgery or the surgical indications per se. In the following, we delineate the current knowledge on response prediction and early response evaluation in selected tumor entities and draw possible conclusions for clinical practice and future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119884     DOI: 10.1007/s00104-006-1270-8

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  51 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 3.  Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review.

Authors:  Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

4.  Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.

Authors:  Pooja R Rohatgi; Paul F Mansfield; Christopher H Crane; Tsung-Teh Wu; Punita K Sunder; William A Ross; Jeffrey S Morris; Peter W Pisters; Barry W Feig; Leonard L Gunderson; Jaffer A Ajani
Journal:  Cancer       Date:  2006-10-01       Impact factor: 6.860

5.  Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation.

Authors:  Rajyalakshmi Luthra; Tsung-Teh Wu; Madan G Luthra; Julie Izzo; Enrique Lopez-Alvarez; Li Zhang; Jaime Bailey; Jeffrey H Lee; Robert Bresalier; Asif Rashid; Stephen G Swisher; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2005-12-12       Impact factor: 44.544

6.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.

Authors:  B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; Laszlo Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

7.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

8.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

9.  ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

Authors:  R Metzger; C G Leichman; K D Danenberg; P V Danenberg; H J Lenz; K Hayashi; S Groshen; D Salonga; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; B Konda; L Leichman
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

10.  The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Authors:  Björn L D M Brücher; Karen Becker; Florian Lordick; Ulrich Fink; Mario Sarbia; Hubert Stein; Raymonde Busch; Frank Zimmermann; Michael Molls; Heinz Höfler; Jörg R Siewert
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

View more
  3 in total

Review 1.  [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy].

Authors:  F Lordick; K Ott; A Sendler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

2.  [Lymphadenectomy with tumors of the upper gastrointestinal tract].

Authors:  C Schuhmacher; A Novotny; K Ott; M Feith; J R Siewert
Journal:  Chirurg       Date:  2007-03       Impact factor: 0.955

Review 3.  [Principles of neoadjuvant therapy].

Authors:  F Lordick
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.